Eszopiclone is a widely used sleep aid, but its clinical benefits remain heavily debated.

Countries & Cities · Published 10 October 2026 Swipe more like this →

In short: Approved in 2004, eszopiclone is a common sedative-hypnotic for insomnia. While it is a top-prescribed medication in the United States, medical authorities have increasingly urged caution, citing minimal efficacy, potential for dependence, and significant safety risks, particularly for the elderly. Understanding its true impact requires looking beyond the marketing.

Eszopiclone, the S-stereoisomer of zopiclone, functions as a positive allosteric modulator on GABA-A receptors. Since its FDA approval in 2004, it has become a staple of insomnia treatment, with over 1 million prescriptions recorded in the United States in 2020 alone. Despite its popularity, the drug's actual clinical impact is often questioned. A 2018 Cochrane review noted only moderate improvements in sleep onset and maintenance, and a controversial 2009 analysis highlighted that in major trials, patients fell asleep only 15 minutes faster on average than those taking a placebo, with no meaningful improvement in next-day functioning.

The safety profile of eszopiclone has drawn significant scrutiny, leading to major shifts in medical guidance. In 2014, the FDA mandated a reduction in the starting dose to 1 milligram due to concerns about next-day impairment, such as driving difficulties. By 2015, the American Geriatrics Society updated its stance to an unambiguous 'avoid' recommendation for elderly patients, citing a lack of efficacy and increased risks of falls, cognitive impairment, and motor vehicle accidents. These concerns are compounded by the drug's potential for physical and psychological dependence, especially in individuals with histories of substance use.

The international landscape for eszopiclone is equally complex. While it is a schedule IV controlled substance in the U.S., it is not widely available in the European Union. In 2009, the European Medicines Agency denied it 'new active substance' status, deeming it too similar to the older, off-patent drug zopiclone. Although it is marketed as Esogno in some European countries today, the drug's history reflects a broader tension between the demand for pharmacological sleep aids and the medical community's preference for non-drug interventions, which are often underutilized despite evidence of their durability and effectiveness.

General information, not professional advice. Spotted an error? Flag the card or see corrections and complaints.

Intellect Plus is a visual educational discovery platform for exploring fascinating facts and ideas. Brain Food, Not Brain Rot. What is Intellect Plus?

Related

• Why the popular sleep aid zopiclone is often no better than older benzodiazepines
• An antidepressant became a go-to sleep drug despite a guideline against it
• Are sleeping pills actually helping you sleep, or just masking the problem?
• Zolpidem is a potent sedative that can trigger complex behaviors while you are asleep.
• Temazepam is a potent sleep aid that carries unique risks among its class.
• The multifaceted architect of modern cinema's most eccentric narratives
• The 1933 discovery that transformed hormone replacement therapy
• Adwa’s 1896 victory kept Ethiopia off the Scramble map
• The Estonian party that transformed from a liberal movement into a conservative stronghold
• How a single African nation resisted the tide of European colonization
• Europe’s last pagan holdouts now run a digital republic
• Why Canada's most common ethnic identity is simply 'Canadian'

More in Countries and other regions · More in Countries & Cities · Latest · A–Z · All topics